Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Injectable Optoelectronic Probe With In Situ Photoactivation and ROS Monitoring for Oxygen-Dependent Metronomic Photodynamic Cancer Therapy.

Created on 11 Aug 2026

Authors

Jagyeong Goo, Gyan Raj Koirala, Taeyeon Lee, Hanhee Cho, Seong Ik Jeon, Wan Su Yun, Jeongrae Kim, Lili Guo, Suyoun Oh, Won-Gun Koh, Jongho Lee, Tae-Il Kim, Kwangmeyung Kim

Published in

Small (Weinheim an der Bergstrasse, Germany). Pages e75168. Aug 10, 2026. Epub Aug 10, 2026.

Abstract

Photodynamic therapy (PDT) offers an effective and minimally invasive approach to cancer treatment; however, its efficacy is intrinsically constrained by limited light penetration, which fails to target deep tumor tissues, and treatment-induced hypoxia arising from the reduction in intratumoral oxygen levels. Here, we report an injectable optoelectronic probe integrating microscale light-emitting diodes (microLEDs) to enable low-frequency metronomic PDT (mPDT), together with a microLED-photodetector system for real-time, in situ oxygen monitoring. We engineered light-activatable prodrug nanoparticles (PNPs) composed of verteporfin (VPF), a cathepsin B-cleavable peptide (FRRG), and doxorubicin (DOX). The self-assembled VPF-FRRG-DOX prodrug forms stable nanoparticles via π-π stacking, remaining inactive under physiological conditions but releasing and activating VPF and DOX in cathepsin B-overexpressing cancer cells during mPDT. In colon tumor-bearing mice, PNPs showed high tumor accumulation via enhanced permeability and retention (EPR) effect, while the microLED-photodetector probe monitored intratumoral in situ oxygen dynamics. Periodic oxygen depletion and recovery at 0.1 Hz for 1.5 h significantly improved therapeutic efficacy (p = 0.0047) compared with continuous PDT. Collectively, oxygen-guided mPDT combined with light-activatable PNPs provides a minimally invasive strategy for synergistic chemo-photodynamic therapy of deep tumors, with favorable systemic and local biocompatibility.

PMID:
42574351
Bibliographic data and abstract were imported from PubMed on 11 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 12
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement